The DOI matches its Crossref record; 93 of the 93 references it cites were found in a registry or an index.
Gemcitabine: Metabolism and molecular mechanisms of action, sensitivity and chemoresistance in pancreatic cancer
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Duxbury, M. S., Ito, H., Zinner, M. J., Ashley, S. W., & Whang, E. E. (2004) · Oncogene · doi:10.1038/sj.onc.1207272 · Cited by 224
RetractedFOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Conroy, T., Desseigne, F., Ychou, M., Bouché, O., Guimbaud, R., Bécouarn, Y., Adenis, A., Raoul, J.-L., Gourgou-Bourgade, S., de la Fouchardière, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1011923 · Cited by 7,810
Spencer, P. M., Cameron, J. L., & Lin, L. (2000) · Cited by 7,202
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
Von Hoff, D. D., Ervin, T., Arena, F. P., Chiorean, E. G., Infante, J., Moore, M., Seay, T., Tjulandin, S. A., Ma, W. W., Saleh, M. N., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1304369 · Cited by 6,712
Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses
Jones, S., Zhang, X., Parsons, D. W., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Kamiyama, H., Jimeno, A., et al. (2008) · Science · doi:10.1126/science.1164368 · Cited by 3,969
Olive, K. P., Jacobetz, M. A., Davidson, C. J., Gopinathan, A., McIntyre, D., Honess, D., Madhu, B., Goldgraben, M. A., Caldwell, M. E., Allard, D., et al. (2009) · Science · doi:10.1126/science.1171362 · Cited by 3,170
Vincent, A., Herman, J., Schulick, R., Hruban, R. H., & Goggins, M. (2011) · The Lancet · doi:10.1016/s0140-6736(10)62307-0 · Cited by 2,586
Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy
Semenza, G. L. (2012) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2012.01.005 · Cited by 1,514
Reck, M., von Pawel, J., Zatloukal, P., Ramlau, R., Gorbounova, V., Hirsh, V., Leighl, N., Mezger, J., Archer, V., Moore, N., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.5466 · Cited by 1,505
Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis
Thayer, S. P., di Magliano, M. P., Heiser, P. W., Nielsen, C. M., Roberts, D. J., Lauwers, G. Y., Qi, Y. P., Gysin, S., Castillo, C. F.-D., Yajnik, V., et al. (2003) · Nature · doi:10.1038/nature02009 · Cited by 1,480
Research works printed but not linked: 13
- Berger, 2013, Successful treatment with nab-paclitaxel and gemcitabine after FOLFIRINOX failure in a patient with metastasized pancreatic adenocarcinoma, Onkologie, 36, 763, 10.1159/000356811 · doi:10.1159/000356811
- Bergman, 2000, Cross-resistance in the 2′,2′-difluorodeoxycytidine (gemcitabine)-resistant human ovarian cancer cell line AG6000 to standard and investigational drugs, Eur. J. Cancer, 36, 1974, 10.1016/S0959-8049(00)00246-X · doi:10.1016/s0959-8049(00)00246-x
- Eda, 1998, The antiproliferative activity of DMDC is modulated by inhibition of cytidine deaminase, Cancer Res., 58, 1165
- Hatzis, 1998, The intracellular localization of deoxycytidine kinase, J. Biol. Chem., 273, 30239, 10.1074/jbc.273.46.30239 · doi:10.1074/jbc.273.46.30239
- Hu, 2011, UMP/CMPK is not the critical enzyme in the metabolism of pyrimidine ribonucleotide and activation of deoxycytidine analogs in human RKO cells, PLoS One, 6, e19490, 10.1371/journal.pone.0019490 · DOI
- Kim, 2011, The C-terminal region of Bfl-1 sensitizes non-small cell lung cancer to gemcitabine-induced apoptosis by suppressing NF-κB activity and down-regulating Bfl-1, Mol. Cancer, 10, 98, 10.1186/1476-4598-10-98 · doi:10.1186/1476-4598-10-98
- Legarza, 2006, New molecular mechanisms of action of camptothecin-type drugs, Anticancer Res., 26, 3301
- Mazzon, 2003, Cytosolic and mitochondrial deoxyribonucleotidases: activity with substrate analogs, inhibitors and implications for therapy, Biochem. Pharmacol., 66, 471, 10.1016/S0006-2952(03)00290-9 · doi:10.1016/s0006-2952(03)00290-9
- Portal, 2014, Sustained response with gemcitabine plus nab-paclitaxel after folfirinox failure in metastatic pancreatic cancer: report of an effective new strategy, Clin. Res. Hepatol. Gastroenterol., 38, e23, 10.1016/j.clinre.2014.01.005 · doi:10.1016/j.clinre.2014.01.005
- Ritzel, 2001, Mol. Membr. Biol., 18, 65, 10.1080/09687680010026313 · DOI
- Sarup, 1989, Regulation of purine deoxynucleoside phosphorylation by deoxycytidine kinase from human leukemic blast cells, Biochem. Pharmacol., 38, 2601, 10.1016/0006-2952(89)90544-3 · doi:10.1016/0006-2952(89)90544-3
- Watanabe, 2012, HMGA-targeted phosphorothioate DNA aptamers increase sensitivity to gemcitabine chemotherapy in human pancreatic cancer cell lines, Cancer Lett., 315, 18, 10.1016/j.canlet.2011.10.005 · doi:10.1016/j.canlet.2011.10.005
- Xu, 1992, Modulation of deoxycytidylate deaminase in intact human leukemia cells. Action of 2′,2′-difluorodeoxycytidine, Biochem. Pharmacol., 44, 1819, 10.1016/0006-2952(92)90077-V · doi:10.1016/0006-2952(92)90077-v
Cited by
Magnetic iron oxide nanoparticles for drug delivery: applications and characteristics
Vangijzegem, T., Stanicki, D., & Laurent, S. (2019) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2019.1554647 · Cited by 548
Seley-Radtke, K. L., & Yates, M. K. (2018) · Antiviral Research · doi:10.1016/j.antiviral.2018.04.004 · Cited by 543
Shukla, S. K., Purohit, V., Mehla, K., Gunda, V., Chaika, N. V., Vernucci, E., King, R. J., Abrego, J., Goode, G. D., Dasgupta, A., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.06.004 · Cited by 540
Pancreatic Cancer Chemoresistance to Gemcitabine
Amrutkar, M., & Gladhaug, I. (2017) · Cancers · doi:10.3390/cancers9110157 · Cited by 448
Drug resistance in pancreatic cancer: Impact of altered energy metabolism
Grasso, C., Jansen, G., & Giovannetti, E. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.03.026 · Cited by 253
Durfee, P. N., Lin, Y.-S., Dunphy, D. R., Muñiz, A. J., Butler, K. S., Humphrey, K. R., Lokke, A. J., Agola, J. O., Chou, S. S., Chen, I.-M., et al. (2016) · ACS Nano · doi:10.1021/acsnano.6b02819 · Cited by 219
Barriers and opportunities for gemcitabine in pancreatic cancer therapy
Beutel, A. K., & Halbrook, C. J. (2023) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00331.2022 · Cited by 150
Natu, J., & Nagaraju, G. P. (2023) · Cancer Letters · doi:10.1016/j.canlet.2023.216382 · Cited by 73
Pham, K., Delitto, D., Knowlton, A. E., Hartlage, E. R., Madhavan, R., Gonzalo, D. H., Thomas, R. M., Behrns, K. E., George, T. J., Hughes, S. J., et al. (2016) · The American Journal of Pathology · doi:10.1016/j.ajpath.2016.02.009 · Cited by 46
Identification of human gene research articles with wrongly identified nucleotide sequences
Park, Y., West, R. A., Pathmendra, P., Favier, B., Stoeger, T., Capes-Davis, A., Cabanac, G., Labbé, C., & Byrne, J. A. (2022) · Life Science Alliance · doi:10.26508/lsa.202101203 · Cited by 37
“…as we also noted examples of SGK and miR-145 articles that analysed the effects of drug treatments of cancer cell lines, we identi fi ed articles that described either cisplatin (29) or gemcitabine (30) treatment of human cancer cell lines and/or cancer patients as a third targeted corpus (Fig 1).”
Chen, G., Svirskis, D., Lu, W., Ying, M., Li, H., Liu, M., & Wen, J. (2021) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2021.118592 · Cited by 36
Liu, Y., Li, Y., Wang, X., Liu, F., Gao, P., Quinn, M. M., Li, F., Merlino, A. A., Benes, C., Liu, Q., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0567 · Cited by 33
Improving Gemcitabine Sensitivity in Pancreatic Cancer Cells by Restoring miRNA-217 Levels
Panebianco, C., Trivieri, N., Villani, A., Terracciano, F., Latiano, T. P., Potenza, A., Perri, F., Binda, E., & Pazienza, V. (2021) · Biomolecules · doi:10.3390/biom11050639 · Cited by 26
Twarog, N. R., Low, J. A., Currier, D. G., Miller, G., Chen, T., & Shelat, A. A. (2016) · PLOS ONE · doi:10.1371/journal.pone.0149439 · Cited by 16
Metadata
- Authors
- de Sousa Cavalcante, L., & Monteiro, G.
- Venue
- European Journal of Pharmacology
- Publisher
- Elsevier BV
- Published
- 2014-10
- Volume
- 741
- Pages
- 8-16
- ISSN
- 0014-2999 (ISSN-L)
- OpenAlex
- W2045246542
- Cited by
- 576
- References
- 93
- FWCI
- 12.78
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Funders
- Fundação de Amparo à Pesquisa do Estado de São Paulo (2009/01303-1, 2011/04938-8)
- Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.